Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review

Affiliations

¹ Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland.
² HEXAL AG (a Sandoz Company), Holzkirchen, Germany.
³ Arthritis and Rheumatic Disease Specialties, Aventura, FL, USA.
⁴ Department of Medicine, Section of Gastroenterology, University of Chicago, Chicago, IL, USA.
⁵ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
⁶ Oregon Medical Research Center, Portland, OR, USA. blauveltconsults@gmail.com.
⁷ Blauvelt Consulting, LLC, Portland, OR, USA. blauveltconsults@gmail.com.

Published Erratum

Piotr Wiland et al. Adv Ther. 2025 Jun.

. 2025 Jun;42(6):2970-2971.

doi: 10.1007/s12325-025-03181-z.

¹ Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland.
² HEXAL AG (a Sandoz Company), Holzkirchen, Germany.
³ Arthritis and Rheumatic Disease Specialties, Aventura, FL, USA.
⁴ Department of Medicine, Section of Gastroenterology, University of Chicago, Chicago, IL, USA.
⁵ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
⁶ Oregon Medical Research Center, Portland, OR, USA. blauveltconsults@gmail.com.
⁷ Blauvelt Consulting, LLC, Portland, OR, USA. blauveltconsults@gmail.com.

No abstract available

Erratum for

Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Wiland P, Both C, Gaylis NB, Cohen RD, Halfvarson J, Lemke L, von Richter O, Blauvelt A. Wiland P, et al. Adv Ther. 2025 Mar;42(3):1360-1392. doi: 10.1007/s12325-024-03098-z. Epub 2025 Feb 5. Adv Ther. 2025. PMID: 39907897 Free PMC article. Review.